Literature DB >> 18833193

An isogenetic myoblast expression screen identifies DUX4-mediated FSHD-associated molecular pathologies.

Darko Bosnakovski1, Zhaohui Xu, Eun Ji Gang, Cristi L Galindo, Mingju Liu, Tugba Simsek, Harold R Garner, Siamak Agha-Mohammadi, Alexandra Tassin, Frédérique Coppée, Alexandra Belayew, Rita R Perlingeiro, Michael Kyba.   

Abstract

Facioscapulohumeral muscular dystrophy (FSHD) is caused by an unusual deletion with neomorphic activity. This deletion derepresses genes in cis; however which candidate gene causes the FSHD phenotype, and through what mechanism, is unknown. We describe a novel genetic tool, inducible cassette exchange, enabling rapid generation of isogenetically modified cells with conditional and variable transgene expression. We compare the effects of expressing variable levels of each FSHD candidate gene on myoblasts. This screen identified only one gene with overt toxicity: DUX4 (double homeobox, chromosome 4), a protein with two homeodomains, each similar in sequence to Pax3 and Pax7. DUX4 expression recapitulates key features of the FSHD molecular phenotype, including repression of MyoD and its target genes, diminished myogenic differentiation, repression of glutathione redox pathway components, and sensitivity to oxidative stress. We further demonstrate competition between DUX4 and Pax3/Pax7: when either Pax3 or Pax7 is expressed at high levels, DUX4 is no longer toxic. We propose a hypothesis for FSHD in which DUX4 expression interferes with Pax7 in satellite cells, and inappropriately regulates Pax targets, including myogenic regulatory factors, during regeneration.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18833193      PMCID: PMC2572182          DOI: 10.1038/emboj.2008.201

Source DB:  PubMed          Journal:  EMBO J        ISSN: 0261-4189            Impact factor:   11.598


  40 in total

1.  Pax7 is required for the specification of myogenic satellite cells.

Authors:  P Seale; L A Sabourin; A Girgis-Gabardo; A Mansouri; P Gruss; M A Rudnicki
Journal:  Cell       Date:  2000-09-15       Impact factor: 41.582

2.  Expression profiling of FSHD muscle supports a defect in specific stages of myogenic differentiation.

Authors:  Sara T Winokur; Yi-Wen Chen; Peter S Masny; Jorge H Martin; Jeffrey T Ehmsen; Stephen J Tapscott; Silvere M van der Maarel; Yukiko Hayashi; Kevin M Flanigan
Journal:  Hum Mol Genet       Date:  2003-09-30       Impact factor: 6.150

3.  Hypomethylation of D4Z4 in 4q-linked and non-4q-linked facioscapulohumeral muscular dystrophy.

Authors:  Petra G M van Overveld; Richard J F L Lemmers; Lodewijk A Sandkuijl; Leo Enthoven; Sara T Winokur; Floor Bakels; George W Padberg; Gert-Jan B van Ommen; Rune R Frants; Silvère M van der Maarel
Journal:  Nat Genet       Date:  2003-11-23       Impact factor: 38.330

4.  FRG1P is localised in the nucleolus, Cajal bodies, and speckles.

Authors:  S van Koningsbruggen; R W Dirks; A M Mommaas; J J Onderwater; G Deidda; G W Padberg; R R Frants; S M van der Maarel
Journal:  J Med Genet       Date:  2004-04       Impact factor: 6.318

5.  HoxB4 confers definitive lymphoid-myeloid engraftment potential on embryonic stem cell and yolk sac hematopoietic progenitors.

Authors:  Michael Kyba; Rita C R Perlingeiro; George Q Daley
Journal:  Cell       Date:  2002-04-05       Impact factor: 41.582

6.  Facioscapulohumeral muscular dystrophy (FSHD) myoblasts demonstrate increased susceptibility to oxidative stress.

Authors:  Sara T Winokur; Kathy Barrett; Jorge H Martin; James R Forrester; Mariella Simon; Rabi Tawil; Seung-Ah Chung; Peter S Masny; Denise A Figlewicz
Journal:  Neuromuscul Disord       Date:  2003-05       Impact factor: 4.296

7.  The regulation of Notch signaling controls satellite cell activation and cell fate determination in postnatal myogenesis.

Authors:  Irina M Conboy; Thomas A Rando
Journal:  Dev Cell       Date:  2002-09       Impact factor: 12.270

8.  Caspase 3 expression correlates with skeletal muscle apoptosis in Duchenne and facioscapulo human muscular dystrophy. A potential target for pharmacological treatment?

Authors:  M Sandri; A H El Meslemani; C Sandri; P Schjerling; K Vissing; J L Andersen; K Rossini; U Carraro; C Angelini
Journal:  J Neuropathol Exp Neurol       Date:  2001-03       Impact factor: 3.685

9.  Pax7 is necessary and sufficient for the myogenic specification of CD45+:Sca1+ stem cells from injured muscle.

Authors:  Patrick Seale; Jeff Ishibashi; Anthony Scimè; Michael A Rudnicki
Journal:  PLoS Biol       Date:  2004-05-11       Impact factor: 8.029

10.  Inappropriate gene activation in FSHD: a repressor complex binds a chromosomal repeat deleted in dystrophic muscle.

Authors:  Davide Gabellini; Michael R Green; Rossella Tupler
Journal:  Cell       Date:  2002-08-09       Impact factor: 41.582

View more
  176 in total

1.  The Krüppel-like factor 15 as a molecular link between myogenic factors and a chromosome 4q transcriptional enhancer implicated in facioscapulohumeral dystrophy.

Authors:  Petr Dmitriev; Andrei Petrov; Eugenie Ansseau; Luiza Stankevicins; Sébastien Charron; Elena Kim; Tomas Jan Bos; Thomas Robert; Ahmed Turki; Frédérique Coppée; Alexandra Belayew; Vladimir Lazar; Gilles Carnac; Dalila Laoudj; Marc Lipinski; Yegor S Vassetzky
Journal:  J Biol Chem       Date:  2011-09-21       Impact factor: 5.157

2.  The activatory long non-coding RNA DBE-T reveals the epigenetic etiology of facioscapulohumeral muscular dystrophy.

Authors:  Miguel Vizoso; Manel Esteller
Journal:  Cell Res       Date:  2012-06-19       Impact factor: 25.617

Review 3.  Developments in RNA splicing and disease.

Authors:  Michael G Poulos; Ranjan Batra; Konstantinos Charizanis; Maurice S Swanson
Journal:  Cold Spring Harb Perspect Biol       Date:  2011-01-01       Impact factor: 10.005

4.  A unifying genetic model for facioscapulohumeral muscular dystrophy.

Authors:  Richard J L F Lemmers; Patrick J van der Vliet; Rinse Klooster; Sabrina Sacconi; Pilar Camaño; Johannes G Dauwerse; Lauren Snider; Kirsten R Straasheijm; Gert Jan van Ommen; George W Padberg; Daniel G Miller; Stephen J Tapscott; Rabi Tawil; Rune R Frants; Silvère M van der Maarel
Journal:  Science       Date:  2010-08-19       Impact factor: 47.728

Review 5.  Facioscapulohumeral muscular dystrophy and DUX4: breaking the silence.

Authors:  Silvère M van der Maarel; Rabi Tawil; Stephen J Tapscott
Journal:  Trends Mol Med       Date:  2011-02-01       Impact factor: 11.951

6.  Estrogens enhance myoblast differentiation in facioscapulohumeral muscular dystrophy by antagonizing DUX4 activity.

Authors:  Emanuela Teveroni; Marsha Pellegrino; Sabrina Sacconi; Patrizia Calandra; Isabella Cascino; Stefano Farioli-Vecchioli; Angela Puma; Matteo Garibaldi; Roberta Morosetti; Giorgio Tasca; Enzo Ricci; Carlo Pietro Trevisan; Giuliana Galluzzi; Alfredo Pontecorvi; Marco Crescenzi; Giancarlo Deidda; Fabiola Moretti
Journal:  J Clin Invest       Date:  2017-03-06       Impact factor: 14.808

7.  RNA transcripts, miRNA-sized fragments and proteins produced from D4Z4 units: new candidates for the pathophysiology of facioscapulohumeral dystrophy.

Authors:  Lauren Snider; Amy Asawachaicharn; Ashlee E Tyler; Linda N Geng; Lisa M Petek; Lisa Maves; Daniel G Miller; Richard J L F Lemmers; Sara T Winokur; Rabi Tawil; Silvère M van der Maarel; Galina N Filippova; Stephen J Tapscott
Journal:  Hum Mol Genet       Date:  2009-04-09       Impact factor: 6.150

8.  Wnt/β-catenin signaling suppresses DUX4 expression and prevents apoptosis of FSHD muscle cells.

Authors:  Gregory J Block; Divya Narayanan; Amanda M Amell; Lisa M Petek; Kathryn C Davidson; Thomas D Bird; Rabi Tawil; Randall T Moon; Daniel G Miller
Journal:  Hum Mol Genet       Date:  2013-07-02       Impact factor: 6.150

9.  Defective regulation of microRNA target genes in myoblasts from facioscapulohumeral dystrophy patients.

Authors:  Petr Dmitriev; Luiza Stankevicins; Eugenie Ansseau; Andrei Petrov; Ana Barat; Philippe Dessen; Thomas Robert; Ahmed Turki; Vladimir Lazar; Emmanuel Labourer; Alexandra Belayew; Gilles Carnac; Dalila Laoudj-Chenivesse; Marc Lipinski; Yegor S Vassetzky
Journal:  J Biol Chem       Date:  2013-10-20       Impact factor: 5.157

10.  The FSHD2 gene SMCHD1 is a modifier of disease severity in families affected by FSHD1.

Authors:  Sabrina Sacconi; Richard J L F Lemmers; Judit Balog; Patrick J van der Vliet; Pauline Lahaut; Merlijn P van Nieuwenhuizen; Kirsten R Straasheijm; Rashmie D Debipersad; Marianne Vos-Versteeg; Leonardo Salviati; Alberto Casarin; Elena Pegoraro; Rabi Tawil; Egbert Bakker; Stephen J Tapscott; Claude Desnuelle; Silvère M van der Maarel
Journal:  Am J Hum Genet       Date:  2013-09-26       Impact factor: 11.025

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.